Negotiating public-health intellectual property licensing agreements to increase access to health technologies
An insider’s story
Bibliographic Data
| ID | 21879627 |
|---|---|
| Authors | Charles Gore (0000-0002-4315-9113, Medicines Patent Pool), Sébastien Morin (0000-0003-4426-326X, Medicines Patent Pool, corresponding author), John‐Arne Røttingen (0000-0002-5587-4296, Medicines Patent Pool), Marie Paule Kieny (0000-0002-5943-6488, Medicines Patent Pool) |
| Year | 2023 |
| Volume | 8 |
| Issue | 9 |
| Pages | e012964 |
| Publication date | 2023-09-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | BMJ Global Health (JOURNAL) |
| Journal identifiers | ISSN: 2059-7908 • E-ISSN: 2059-7908 |
| Publisher | BMJ (PUBLISHER • GB) |
| DOI | 10.1136/bmjgh-2023-012964 |
| PMID | 37669799 |
| OpenAlex | W4386441323 |
| Language | EN |
| Citations received | 5 |
| References cited | 25 |
Public health voluntary licensing of intellectual property has successfully been applied to increase access to medicines in certain disease areas, producing health benefits and economic savings, particularly in low-income and middle-income countries. There is however limited understanding of the intricacies of the approach, the modalities by which it works in practice, its levers and the trade-offs made. Such knowledge may be critical in deciding what role licensing should have in pandemic preparedness and equitable access to health technologies more broadly. This paper examines the case for licensing, the considerations for balancing public health needs, the challenges of negotiations, and the processes for validating proposed agreements. No access mechanism is perfect, but evidence suggests that public-health licensing has an important role to play, although it remains underused. Understanding some of the realities, strengths, limitations and complexities of applying the model may help calibrate expectations and develop incentives to expand its applications
Business · Economics · Incentive · Insider · Intellectual property · Negotiation · Political science · Public economics · Public health · Public relations · Biotechnology and Related Fields · Health Systems, Economic Evaluations, Quality of Life · Medicine · Pharmaceutical Economics and Policy
TRIPS flexibilities help change policy and practice to increase access to medicines
Lessons learnt from Covid-19 to reduce mortality and morbidity in the Global South
‘Our project, your problem?’ A case study of the WHO’s mRNA technology transfer programme in South Africa
Intellectual property licensing of therapeutics during the Covid-19 crisis
Making Advanced Therapies Affordable and Accessible
| Citations per year | 2.5 |
|---|---|
| Citation span | 2024 - 2026 (3) |
| Highly cited | No |